HH1129955_XHANCE_Infographic_v3_LO5 - XHANCE® (fluticasone propionate)

XHANCE is a corticosteroid indicated for the treatment of nasal polyps in patients 18 years of age or older.

  • Full Prescribing Information
  • Instructions for Use
  • Patient Information
  • Patient Site
Resources Email Preferences
XHANCE® (fluticasone propionate) nasal spray 93 mcg logo
  • Nasal Polyps
    • About Nasal Polyps
    • Diagnosing Nasal Polyps
    • Treating Nasal Polyps
  • Exhalation Delivery System
  • About XHANCE
    • Mechanism of Delivery
    • When to Use
    • FAQs
  • Clinical Trial Results
    • Efficacy
    • Safety
  • The Impact of XHANCE
    • Peer Insights
    • Clinical Examples
  • Dosing and Administration
  • Affordability
    • XHANCE Xtended Patient Support
    • Retail Pharmacies
IMPORTANT SAFETY INFORMATION
IMPORTANT SAFETY INFORMATION

CONTRAINDICATIONS:
Hypersensitivity to any ingredient in XHANCE.

WARNINGS AND PRECAUTIONS:

  • Local Nasal Effects: epistaxis, erosion, ulceration, septal perforation, Candida albicans infection, and impaired wound healing. Monitor patients periodically for signs of possible changes on the nasal mucosa. Avoid use in patients with recent nasal ulcerations, nasal surgery, or nasal trauma until healing has occurred.
  • Close monitoring for glaucoma and cataracts is warranted.
  • Hypersensitivity reactions (e.g., anaphylaxis, angioedema, urticaria, contact dermatitis, rash, hypotension, and bronchospasm) have been reported after administration of fluticasone propionate. Discontinue XHANCE if such reactions occur.
  • Immunosuppression: potential increased susceptibility to or worsening of infections (e.g., existing tuberculosis; fungal, bacterial, viral, or parasitic infection; ocular herpes simplex). Use with caution in patients with these infections. More serious or even fatal course of chickenpox or measles can occur in susceptible patients.
  • Hypercorticism and adrenal suppression may occur with very high dosages or at the regular dosage in susceptible individuals. If such changes occur, discontinue XHANCE slowly.
  • Patients with major risk factors for decreased bone mineral content should be monitored and treated with established standards of care.

ADVERSE REACTIONS:
The most common adverse reactions (incidence ≥ 3%) are epistaxis, nasal septal ulceration, nasopharyngitis, nasal mucosal erythema, nasal mucosal ulcerations, nasal congestion, acute sinusitis, nasal septal erythema, headache, and pharyngitis.

DRUG INTERACTIONS:
Strong cytochrome P450 3A4 inhibitors (e.g., ritonavir, ketoconazole): Use not recommended. May increase risk of systemic corticosteroid effects.

USE IN SPECIFIC POPULATIONS:
Hepatic impairment. Monitor patients for signs of increased drug exposure.

INDICATION AND USAGE: XHANCE is a corticosteroid indicated for the treatment of nasal polyps in patients 18 years of age or older.

Please see full Prescribing Information, including Instructions for Use.

  • Contact Us
  • Privacy Policy
  • Terms of Use
  • Site Map

This site is intended for healthcare professionals in the United States.
OPTINOSE®, XHANCE®, EXHALATION DELIVERY SYSTEM™, and EDS® are trademarks of OptiNose Inc.

Footer Logo
©2022 OptiNose US, Inc. All rights reserved.  XHA-21-10236  07/2022

Are you a US healthcare professional?

No

You are about to leave the XHANCE HCP website.

Are you sure?

Yes
Your browser doesn't support HTML5 video tag.